InvestorsHub Logo
Followers 103
Posts 7202
Boards Moderated 0
Alias Born 03/29/2019

Re: exwannabe post# 535088

Friday, 11/18/2022 12:36:09 PM

Friday, November 18, 2022 12:36:09 PM

Post# of 705747
Irrelevant statements even after a highly successful P3 trial and publication of results that have been reviewed by a top journal.

Conclusions
This phase 3, nonrandomized, externally controlled trial found
that the addition of DCVax-L to SOC was associated with a clinically
meaningful and statistically significant extension of overall
survival in both nGBM and rGBM. Treatment with DCVax-L
also had an excellent safety profile and noteworthy tails of long-term
survival curves.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News